AVANIR Pharmaceuticals Invites Investors to the Bank of America and the UBS Global Life Sciences Conference Webcasts
SAN DIEGO--(BUSINESS WIRE)--Sept. 16, 2005--AVANIR Pharmaceuticals (AMEX:AVN) will be presenting at Bank of America's 35th Annual Investment Conference on Thursday, September 22, 2005 at 7:30 a.m. PT in San Francisco, and at the UBS Global Life Sciences Conference on Thursday, September 29, 2005 at 9:00 a.m. ET in New York. AVANIR's President and Chief Executive Officer, Eric K. Brandt, will be presenting at the conferences.
The live webcasts of the presentations will be accessible through AVANIR's corporate website at http://www.avanir.com. To access the webcasts, log on to AVANIR's site fifteen minutes prior to the presentation to register and download any necessary audio software. Archived versions of the presentations will be available until October 30, 2005.
AVANIR Pharmaceuticals is focused on developing and commercializing novel therapeutic products for the treatment of chronic diseases. AVANIR's product candidates address therapeutic markets that include central nervous system and cardiovascular disorders, inflammation, and infectious disease. AVANIR recently submitted to the FDA the last reviewable unit of its "rolling" new drug application for Neurodex(TM) for the treatment of pseudobulbar affect. Additionally, AVANIR has initiated a Phase 3 clinical trial of Neurodex(TM) for the treatment of diabetic neuropathic pain. AVANIR has active collaborations with two international pharmaceutical companies: Novartis International Pharmaceutical Ltd. for the treatment of inflammatory disease and AstraZeneca UK Limited for the treatment of cardiovascular disease. The Company's first commercialized product, Abreva(R), is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores. Further information about AVANIR can be found at www.avanir.com.
The information contained in this press release, including any forward-looking statements contained herein, should be reviewed in conjunction with the company's most recent Annual Report on Form 10-K and other publicly available information regarding the company. Copies of such information are available from the company upon request. Such publicly available information sets forth many risks and uncertainties related to the company's business and technology. Forward-looking statements often contain such words like "estimate," "anticipate," "believe," "plan" or "expect." The company disclaims any intent or obligation to update these forward-looking statements. Final review decisions made by the FDA and other regulatory agencies concerning clinical trial results are unpredictable and outside the influence and/or control of the company.
CONTACT: AVANIR Pharmaceuticals Patrice Saxon, 858-622-5202 email@example.com SOURCE: AVANIR Pharmaceuticals